主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
AVBP
#2111
ArriVent BioPharma, Inc. Common Stock
22.9
7
+0.22%
版块:
基础:
利润货币:
日范围
年范围
日变化
+0.22%
每月变动
-1.20%
6个月变化
+19.57%
年变化
-4.01%
前一天收盘价
22.9
2
Open
22.9
3
Bid
Ask
Low
22.9
3
High
22.9
7
交易量
76
市场
股票
医疗保健
AVBP
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Dividends per share
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
新闻
Cantor Fitzgerald重申ArriVent股票评级为"增持"
ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald
Oppenheimer维持ArriVent BioPharma股票"跑赢大盘"评级
Oppenheimer reiterates Outperform rating on ArriVent BioPharma stock
ArriVent BioPharma (AVBP): Its Leading Asset, Furmonertinib, Supports A Cautious Buy
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP)
Cantor Fitzgerald 给予ArriVent BioPharma股票"增持"评级
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating
ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug
BTIG给ArriVent BioPharma股票首次评级为"买入",看好其肿瘤治疗潜力
ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential
Truist证券给予ArriVent BioPharma买入评级,看好其肺癌药物前景